Treatment of HIV infection. Tolerability of commonly used antiretroviral agents (Q41175137)

27 September 2017

1 reference

title

Treatment of HIV infection. Tolerability of commonly used antiretroviral agents (English)

1 reference

27 September 2017

D W Notermans

1

1 reference

27 September 2017

R van Leeuwen

series ordinal

2

1 reference

27 September 2017

J M Lange

series ordinal

3

1 reference

27 September 2017

publication date

1 September 1996

1 reference

27 September 2017

1 reference

27 September 2017

volume

15

1 reference

27 September 2017

issue

3

1 reference

27 September 2017

page(s)

176-187

1 reference

Retinal Toxicity in Human Immunodeficiency Virus–infected Children Treated With 2′,3′-Dideoxyinosine

27 September 2017

cites work

1 reference

12 December 2020

A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.

1 reference

12 December 2020

Safety and tolerance of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Study Group of the AIDS Clinical Trials Group of the National Inst

1 reference

12 December 2020

Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication

1 reference

12 December 2020

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

1 reference

12 December 2020

Resistance, drug failure, and disease progression

1 reference

12 December 2020

Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS.

1 reference

12 December 2020

Foscarnet for suppression of human immunodeficiency virus replication

1 reference

12 December 2020

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

12 December 2020

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

1 reference

12 December 2020

Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study

1 reference

12 December 2020

Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient

1 reference

12 December 2020

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

1 reference

12 December 2020

The combined toxicity of azidothymidine and antimycobacterial agents. A retrospective study

1 reference

12 December 2020

Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017)

1 reference

12 December 2020

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group

1 reference

12 December 2020

The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group

1 reference

12 December 2020

Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.

1 reference

12 December 2020

Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group

1 reference

12 December 2020

The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)

1 reference

12 December 2020

Lactic acidosis complicating the acquired immunodeficiency syndrome

1 reference

12 December 2020

Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group

1 reference

12 December 2020

The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection

1 reference

12 December 2020

A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group

1 reference

12 December 2020

A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection

1 reference

12 December 2020

The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study

1 reference

12 December 2020

Rates and risk factors for adverse events associated with didanosine in the expanded access program

1 reference

12 December 2020

Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group

1 reference

12 December 2020

Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study

1 reference

12 December 2020

Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex

1 reference

12 December 2020

1 reference

12 December 2020

Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity

1 reference

12 December 2020

Hepatic disease in patients with the acquired immune deficiency syndrome (AIDS).

1 reference

12 December 2020

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Efficacy of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with AIDS

1 reference

12 December 2020

Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.

1 reference

12 December 2020

Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma

1 reference

12 December 2020

Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program

1 reference

12 December 2020

A clinicopathologic report of the retinal lesions associated with didanosine

1 reference

12 December 2020

Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial

1 reference

12 December 2020

Prevalence and patterns of use of concomitant medications among participants in three multicenter human immunodeficiency virus type I clinical trials. AIDS Clinical Trials Group (ACTG).

1 reference

12 December 2020

Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089.

1 reference

12 December 2020

HIV therapy advances. Update on a proteinase inhibitor

1 reference

12 December 2020

Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study

1 reference

12 December 2020

A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group

1 reference

12 December 2020

Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy

1 reference

12 December 2020

2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial

1 reference

12 December 2020

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group

1 reference

12 December 2020

Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.

1 reference

12 December 2020

Safety and activity of saquinavir in HIV infection

1 reference

12 December 2020

Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma

1 reference

12 December 2020

Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro

1 reference

12 December 2020

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

12 December 2020

Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection

1 reference

12 December 2020

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex

1 reference

12 December 2020

Zidovudine-induced hepatotoxicity

1 reference

12 December 2020

Time to hit HIV, early and hard.

1 reference

12 December 2020

Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex

1 reference

12 December 2020

Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS)

1 reference

12 December 2020

Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection

1 reference

12 December 2020

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

1 reference

12 December 2020

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

1 reference

12 December 2020

Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients

1 reference

12 December 2020

Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase

1 reference

12 December 2020

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

1 reference

12 December 2020

Metabolic, hepatic and muscular changes during zidovudine therapy: a drug-induced mitochondrial disease?

1 reference

12 December 2020

Biologic effects and safety of stavudine: overview of phase I and II clinical trials

1 reference

12 December 2020

A pilot study of low-dose zidovudine in human immunodeficiency virus infection

1 reference

12 December 2020

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

12 December 2020

Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

1 reference

12 December 2020

Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group

1 reference

12 December 2020

2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial

1 reference

12 December 2020

Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee

1 reference

12 December 2020

Combination therapy: more effective control of HIV type 1?

1 reference

12 December 2020

The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro

1 reference

12 December 2020

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

12 December 2020

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

1 reference

12 December 2020

Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program

1 reference

12 December 2020

Phase I study of 2′-3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine

1 reference

12 December 2020

A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group

1 reference

12 December 2020

Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study

1 reference

12 December 2020

Combination Antiretroviral Therapy

1 reference

12 December 2020

In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha

1 reference

12 December 2020

Mitochondrial toxicity--new adverse drug effects

1 reference

12 December 2020

Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI)

1 reference

12 December 2020

Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.

1 reference

12 December 2020

A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection

1 reference

12 December 2020

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study

1 reference

12 December 2020

Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group

1 reference

12 December 2020

Zidovudine-associated myopathy

1 reference

12 December 2020

Issues in combination antiretroviral therapy: a review

1 reference

12 December 2020

Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups

1 reference

12 December 2020

Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus

1 reference

12 December 2020

Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection

1 reference

12 December 2020

Strategies for antiviral therapy in AIDS.

1 reference

12 December 2020

Hepatomegaly with severe steatosis in HIV-seropositive patients

1 reference

12 December 2020

Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.

1 reference

12 December 2020

Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy

1 reference

12 December 2020

Mitochondrial myopathy caused by long-term zidovudine therapy

1 reference

12 December 2020

A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection

1 reference

12 December 2020

Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma

1 reference

12 December 2020

Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS)

1 reference

12 December 2020

Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine

1 reference

12 December 2020

Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study

1 reference

12 December 2020

Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group

1 reference

12 December 2020

Combined zidovudine and interferon-alpha treatment in patients with AIDS-associated Kaposi's sarcoma

1 reference

12 December 2020

10.2165/00002018-199615030-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

27 September 2017

1027770827

0 references

1 reference